Evidence map›Paper›PMID 40475643›Full record

ArticlebioRxiv : the preprint server for biology2025

Complexoform-restricted covalent TRMT112 ligands that allosterically agonize METTL5.

F Wieland Goetzke, Steffen M Bernard, Cheng-Wei Ju, Jonathan Pollock, Kristen E DeMeester, Jacob Gross, Gabriel M Simon, Chuan He, Bruno Melillo, Benjamin F Cravatt

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

F Wieland GoetzkeDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.
Steffen M BernardVividion Therapeutics, San Diego, CA, USA.
Cheng-Wei JuDepartment of Chemistry, Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, USA.
Jonathan PollockVividion Therapeutics, San Diego, CA, USA.
Kristen E DeMeesterDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.
Jacob GrossVividion Therapeutics, San Diego, CA, USA.
Gabriel M SimonVividion Therapeutics, San Diego, CA, USA.
Chuan HeDepartment of Chemistry, Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, USA.
Bruno MelilloDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.
Benjamin F CravattDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Chemical Proteomic Platforms for Radically Expanding Cancer DruggabilityR35CA231991 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BENJAMIN F CRAVATT · 2018 to 2026
$9.5M
NCI NIH HHS R35 CA231991NIGMS NIH HHS P30 GM124169
6 · The paper itself

Abstract

Adaptors serve as hubs to regulate diverse protein complexes in cells. This multitude of functions can complicate the study of adaptors, as their genetic disruption may simultaneously impair the activities of several compositionally distinct complexes (or adaptor 'complexoforms'). Here we describe the chemical proteomic discovery of bicyclopyrrolidine acrylamide stereoprobes that react with cysteine-100 (C100) of the methyltransferase (MT) adaptor TRMT112 in human cells. Curiously, the stereoprobes showed negligible reactivity with uncomplexed recombinant TRMT112, and we found that this interaction was restored excluively in the presence of METTL5, but not other MTs. A co-crystal structure revealed stereoprobe binding to a composite pocket proximal to C100 of TRMT112 that is templated by METTL5 and absent in other TRMT112:MT complexes. Structural rearrangements promoted by stereoprobe binding in turn lead to allosteric agonism of METTL5, thus revealing how covalent ligands targeting a pleiotropic adaptor can confer partner-specific functional effects through reactivity with a single complexoform.

Identifiers

PMID40475643
PMCPMC12139762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.